PP
SBBP

Paloma Partners’s Strongbridge Biopharma plc. SBBP Stock Holding History

Paloma Partners’s Portfolio SBBP Stock Details SBBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-136,199
Closed -$817K – 2071
2018
Q2 		$817K Buy
+136,199
New +$996K 0.01% 796
2018
Q1 		– Sell
-20,922
Closed -$152K – 2360
2017
Q4 		$152K Buy
+20,922
New +$131K ﹤0.01% 1764

Other funds holding SBBP

CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
HCS
Harvest Capital Strategies San Francisco, California $73.7M AUM 7.47% 1-Year Est. Return

Paloma Partners's SBBP Position: Q3 2018 in Review

Paloma Partners sold out of Strongbridge Biopharma plc. (SBBP) in Q3 2018, closing a stake of 136,199 shares — an estimated $817K sold.

Paloma Partners first reported a position in SBBP in Q4 2017 and held it in 2 quarters. The position peaked at $817K in Q2 2018. 49 funds tracked by Wall St. Rank hold SBBP as of Q3 2018.

  • Paloma Partners reported no remaining Strongbridge Biopharma plc. position as of Q3 2018 after selling out during the quarter.
  • Paloma Partners sold 136,199 Strongbridge Biopharma plc. shares in Q3 2018, an estimated $817K.
  • Paloma Partners first reported a position in Strongbridge Biopharma plc. in Q4 2017 and held it in 2 quarters.
  • Paloma Partners's Strongbridge Biopharma plc. position peaked at $817K in Q2 2018.
  • 49 funds tracked by Wall St. Rank held Strongbridge Biopharma plc. as of Q3 2018.

Based on Paloma Partners's 13F filing for Q3 2018, filed 14 Nov 2018.